Biotie Therapies - Company Announcement

Biotie Successfully Completes Imaging Study with SYN120

Biotie Therapies Corp.          Stock Exchange Release    1 March 2012 at 9.00
a.m.

Biotie Successfully Completes Imaging Study with SYN120

Biotie today announced the completion of a Phase 1 clinical study using positron
emission tomography (PET) imaging for its 5-HT6 receptor antagonist SYN120.  The
study was designed to establish the appropriate dose of SYN120 for Phase 2
trials in cognitive disorders, including Alzheimer's disease and schizophrenia.

The PET study was conducted at the Johns Hopkins University School of Medicine
in the United States. It evaluated occupancy of the 5-HT6 receptor in the brain
in nine healthy volunteers who were treated with different doses of SYN120. The
results demonstrate that target levels of receptor occupancy expected for
efficacy can be achieved with SYN120 doses that are an order of magnitude lower
than those that have previously been shown to be safe and well tolerated for up
to two weeks in healthy older volunteers."We are extremely pleased with the outcome of this study," commented Dr Timo
Veromaa, Biotie's Chief Executive Officer. "These data suggest that Phase 2
trials can be conducted at doses that are fully expected to be therapeutic and
yet maintain a wide safety margin. We are now in the process of preparing a
Phase 2 enabling package to be submitted to Roche for their evaluation."

Turku, 1 March 2012

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail:virve.nurmi@biotie.com

Media contact:

Julie Walters, Tudor Reilly
Office: +44 (0) 20 7034 3201
Mobile +44 (0) 775 362 6967

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com

About SYN120

SYN120 is a potent, selective and orally bioavailable 5-HT6 receptor antagonist,
exclusively targeting regions in the brain associated with memory function.
SYN120 has been shown to enhance cognition in various preclinical models, and
has completed single and multiple-ascending dose studies in Phase 1.

The compound was discovered at Roche and is being developed by Biotie under a
licensing agreement. Roche retains an opt-in right on the 5-HT6 program which
can be exercised on completion of this imaging study. Biotie will provide Roche
with an extensive package of preclinical and clinical data to facilitate their
decision.

About Biotie

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease,
Alzheimer's disease and other cognitive disorders, alcohol and drug dependence
(addiction) and post traumatic stress disorder), and inflammatory and fibrotic
liver disease.

The company has a strong and balanced development portfolio with several
innovative small molecule and biological drug candidates at different stages of
clinical development. Biotie's products address diseases with high unmet medical
need and significant market potential.

Partnerships with top-tier pharmaceutical partners are in place for several
programs as well as a strategic collaboration with UCB Pharma S.A. The Marketing
Authorization Application for Biotie's most advanced product, Selincro(TM)
(nalmefene) for alcohol dependence was filed in the EU by our partner H.
Lundbeck A/S and was accepted for review by the European Medicines Agency in
December 2011.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.


[HUG#1590383]